Product image of Granissetrom Orchid Europe (Granisetron) supplied by GNH India

Granissetrom Orchid Europe

Active Ingredient:
Granisetron
Origin:
EU

Granissetrom Orchid Europe (Granisetron)

Granissetrom Orchid Europe is an oral, prescription medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist. It is marketed in the European Union and is formulated for systemic use to help prevent nausea and vomiting associated with chemotherapy or surgery. The product is supplied without a listed strength, reflecting its status as a generic formulation of granisetron for oral administration, and is intended for use under supervision.

Manufacturer / TM Owner

Emona Biopharma D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron, the active component of Granissetrom Orchid Europe, is employed as an antiemetic in several clinical settings.

  • Prevention of chemotherapy‑induced nausea and vomiting, especially with highly emetogenic regimens.
  • Prevention of postoperative nausea and vomiting following surgical procedures.
  • Adjunct therapy for radiation‑induced nausea and vomiting.
  • Management of nausea associated with diagnostic contrast agents.
  • Use in patients receiving moderately emetogenic chemotherapy to reduce acute emesis.

Side Effects

The safety profile of granisetron includes both frequently observed and less common adverse reactions.

Common

  • Headache.
  • Constipation.
  • Dizziness.
  • Fatigue.

Serious

  • Severe allergic reaction (anaphylaxis).
  • Cardiac arrhythmias, including QT interval prolongation.
  • Severe constipation or ileus leading to bowel obstruction.
  • Serotonin syndrome, particularly when combined with other serotonergic agents.

Precautions & Warnings

When prescribing Granissetrom Orchid Europe, clinicians should consider several precautionary measures.

  • Review the patient’s cardiac history and baseline ECG, especially if there is a risk of QT prolongation.
  • Use cautiously in individuals with electrolyte imbalances (e.g., hypokalemia, hypomagnesemia).
  • Avoid in patients with known hypersensitivity to granisetron or other 5‑HT3 antagonists.
  • Assess renal and hepatic function; dose adjustment may be necessary in impairment.
  • Pregnancy and lactation status should be evaluated, as safety data are limited.
  • Monitor for signs of constipation or bowel obstruction during therapy.

Avoid Interactions

Granisetron may interact with other medications, requiring attention to avoid or adjust co‑administration.

Avoid

  • Concurrent use of other 5‑HT3 receptor antagonists.
  • Co‑administration with drugs known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

  • Strong CYP3A4 inhibitors (e.g., ketoconazole) that can increase granisetron plasma levels.
  • CYP3A4 inducers (e.g., rifampin) that may reduce its effectiveness.
  • Medications affecting cardiac conduction such as methadone or other opioids.

Frequently Asked Questions

Granissetrom Orchid Europe is a prescription oral tablet that contains granisetron, a selective 5‑HT3 receptor antagonist used to prevent nausea and vomiting.

Granisetron is commonly prescribed to prevent chemotherapy‑induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

Granisetron blocks serotonin 5‑HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing serotonin‑mediated stimulation of the vomiting center.

Safety of granisetron during pregnancy has not been fully established; it should only be used if the potential benefit outweighs the potential risk and after consulting a healthcare professional.

Common side effects include headache, constipation, dizziness, and fatigue, which are usually mild and transient.

Serious reactions such as severe allergic response (rash, swelling, difficulty breathing), cardiac arrhythmias, or signs of serotonin syndrome require urgent medical care.

An ECG is recommended for patients with a history of cardiac disease or risk factors for QT prolongation before initiating therapy.

Concurrent use with other 5‑HT3 antagonists should be avoided, but combination with drugs of different classes may be considered under medical supervision.

Impairment of kidney or liver function may require dose adjustment; clinicians should evaluate organ function and modify the regimen accordingly.

Certain OTC drugs that affect cardiac conduction or prolong the QT interval, such as some antihistamines, should be used with caution and discussed with a pharmacist or physician.

Patients should contact their healthcare provider promptly, as severe constipation can lead to bowel obstruction and may require medical intervention.

No, granisetron is classified as a prescription‑only medication (Rx) throughout the European Union.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT